Merck & Co., Inc. (JOBS) Abandons One Migraine Drug MK-3207, Pursues Another

Published: Sep 11, 2009

Bookmark and Share

PHILADELPHIA--(BUSINESS WIRE)--Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine. The Company provided this update in conjunction with poster presentations of new data from two Phase III clinical studies of telcagepant at the 14th International Headache Congress.

Back to news